Transcriptional profiling of human breast tumor samples before and after treatment with chemotherapy with and without bevacizumab.
Ontology highlight
ABSTRACT: Molecular responses in tumors after treatment with antiangiogenic therapy are largely unknown. In this experiment, we have assessed the efficacy of bevacizumab in HER2 negative breast carcinomas treated with a neoadjuvant chemotherapy regimen consisting of sequential anthracycline and taxane. Whole genome gene expression profiles of the tumors before, during and after treatment are compared to shed light on change in transcriptional profile following therapy.
ORGANISM(S): Homo sapiens
SUBMITTER: Olav Engebråten
PROVIDER: E-MTAB-4439 | biostudies-arrayexpress |
REPOSITORIES: biostudies-arrayexpress
ACCESS DATA